IMPEDIMED LIMITED — Board/Management Information 2015

May 10, 2015

==> picture [109 x 100] intentionally omitted <==

----- Start of picture text ----- ASX: IPD----- End of picture text -----

11 May 2015

ASX ANNOUNCEMENT

MANAGNG DIRECTOR APPOINTMENT

Brisbane, Australia – ImpediMed Limited (ASX: IPD) (“the Company”), is pleased to announce the appointment of Mr Richard Carreon as Managing Director of the company effective 9 May 2015. Mr Carreon is currently the Chief Executive Officer of the Company.

Cherrell Hirst Chairman

For further information contact: Richard Carreon, ImpediMed CEO Morten Vigeland, ImpediMed CFO T: +1 (760) 585-2100

Kyahn Williamson, Buchan Investor and Media Relations T: +61 3 9866 4722

E: kwilliamson@buchanwe.com.au

About ImpediMed

ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

For more information, visit: www.impedimed.com.au

Page 1 of 1